Non Small Cell Lung Cancer Clinical Trials

202 studies are recruiting for non small cell lung cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 7

1. A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

   This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study nea…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Colorado Cancer Center, Aurora, Colorado

   Locations

   5 in total

   Run by

   7 Hills Pharma, LLC

   See if you can join NCT06362369 on ClinicalTrials.gov

2. Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

   This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tum…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic Scottsdale, Scottsdale, Arizona

   Locations

   15 in total

   Run by

   Tango Therapeutics, Inc.

   See if you can join NCT06810544 on ClinicalTrials.gov

3. Pulmonary Rehabilitation in Advanced Lung Cancer Survivors

   This study is for people who have previously been diagnosed with advanced stage non-small cell lung cancer (NSCLC). Many people with advanced stage NSCLC have trouble breathing and feel tired. People may be eligible for this study if they have advanced stage NSCLC and feel short of breath some of t…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio

   Run by

   Case Comprehensive Cancer Center

   See if you can join NCT07104630 on ClinicalTrials.gov

4. Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases

   This is a single arm phase 2 trial is to evaluate the efficacy of SRS plus adagrasib for the treatment of brain metastases for patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC). A total of 30 patients will be enrolled on this study.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Ohio State University Comprehensive Cancer Center, Columbus, Ohio

   Locations

   3 in total

   Run by

   Ryan Gentzler, MD

   See if you can join NCT06248606 on ClinicalTrials.gov

5. A Study of VET3-TGI in Patients With Solid Tumors

   VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or whe…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   USC/Norris Comprehensive Cancer Center, Los Angeles, California

   Locations

   7 in total

   Run by

   KaliVir Immunotherapeutics

   See if you can join NCT06444815 on ClinicalTrials.gov

6. This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

   This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have exhausted all standard therapy available or are intolerant of the same.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dana Farber Cancer Institute, Boston, Massachusetts

   Locations

   3 in total

   Run by

   Zumutor Biologics Inc.

   See if you can join NCT06451497 on ClinicalTrials.gov

7. KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLC

   This is a single institution, Phase 1 study for patients with Stage III/IV unresectable Kirsten rat sarcoma (KRAS) mutated NSCLC to evaluate safety of the pooled mutant-KRAS peptide vaccine (KRAS peptide vaccine) with polyinosinic-polycytidylic acid (poly-ICLC) adjuvant in combination with chemoimm…

   Stage

   Phase 1

   Ages

   18 to 100

   Site

   Johns Hopkins University, Baltimore, Maryland

   Run by

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

   See if you can join NCT05254184 on ClinicalTrials.gov

8. Phase 2 Study of Fingolimod in Lung Cancers

   This is a single-institution, open-labeled study using fingolimod (FTY720/Gilenya) in patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) who have progressed on chemo-immunotherapy. The study design will be a 6 patient safety lead-in with 2 cohorts of patients for eff…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina

   Run by

   Medical University of South Carolina

   See if you can join NCT06424067 on ClinicalTrials.gov

9. Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC

   This study is to determine if Healthy Donor FMT (hdFMT) improves the body's ability to fight cancer in patients with relapsed/refractory PD-L1 Positive NSCLC.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

   Run by

   Diwakar Davar

   See if you can join NCT05669846 on ClinicalTrials.gov

10. Using E-Nose Technology to Track Treatment Response in People With Non-Small Cell Lung Cancer

    The researchers are doing this study to test the ability of a new technology called breathprinting, or electronic nose (E-Nose), to measure changes in certain chemicals in the breath before and after standard neoadjuvant therapy in people with NSCLC.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07218601 on ClinicalTrials.gov

11. A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

    The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants w…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California San Diego (UC San Diego) Health - Jacobs Medical Center - Moores Cancer Center, La Jolla, California

    Locations

    26 in total

    Run by

    Frontier Medicines Corporation

    See if you can join NCT06244771 on ClinicalTrials.gov

12. First-in-human Study of Interferon-y PET Imaging to Assess Response to Immunotherapy

    The goal of this clinical trial is to investigate the use of [89Zr]Zr-DFO-emapalumab as an IFN-γ PET imaging agent to detect lesions and response to therapy among treatment-naïve non-small cell lung cancer (NSCLC) patients. PET scans following the imaging agent will be completed prior to and about …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Karmanos Cancer Institute, Detroit, Michigan

    Run by

    Nerissa T. Viola

    See if you can join NCT06439914 on ClinicalTrials.gov

13. Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

    This is a Phase 1, multicenter, open-label dose escalation study to determine the safety and tolerability of intratumoral (IT) injection of tolododekin alfa (ANK-101) in participants with advanced solid tumors who have progressed during or after receiving standard of care (SOC) therapy or who will …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    National Cancer Institute, Bethesda, Maryland

    Locations

    5 in total

    Run by

    Ankyra Therapeutics, Inc

    See if you can join NCT06171750 on ClinicalTrials.gov

14. Repositioning Immunotherapy in VetArans With Lung Cancer

    This study is a multicenter Phase II single arm trial to assess the safety and efficacy of chemotherapy and immunotherapy followed by radiotherapy in patients with unresectable Stage III NSCLC.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven, Connecticut

    Locations

    7 in total

    Run by

    VA Office of Research and Development

    See if you can join NCT06275360 on ClinicalTrials.gov

15. A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors

    This study is a Phase 1/2, first-in-human, open-label, clinical trial to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of HMBD-501 in patients with advanced-stage, relapsed and/or refractory human epidermal growth factor receptor 3 (HER3)-expressing solid tumors. The st…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, La Jolla, California

    Locations

    7 in total

    Run by

    Hummingbird Bioscience

    See if you can join NCT06956690 on ClinicalTrials.gov

16. Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

    This study is being done to determine if stereotactic body radiotherapy (SBRT) when delivered to all sites of disease in participants with 1-5 metastases will increase the length of time before participants' disease gets worse.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Hartford Healthcare, Hartford, Connecticut

    Locations

    12 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT03808337 on ClinicalTrials.gov

17. Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer

    This study investigates fluorine-18-AlphaVBeta6-BP ([18F]-αvβ6-BP) as a Positron Emission (PET) imaging agent in Non-Small Cell Lung Cancer (NSCLC) patients with brain metastases. Investigators hypothesize that [18F]-αvβ6-BP PET/Computed Tomography (CT) is a sensitive tool for disease assessment in…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of California Davis Comprehensive Cancer Center, Sacramento, California

    Run by

    University of California, Davis

    See if you can join NCT05452005 on ClinicalTrials.gov

18. A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)

    This study is designed to evaluate safety and anti-tumor activity of DZD6008 in patients with advanced NSCLC with EGFR mutations.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York

    Locations

    5 in total

    Run by

    Dizal Pharmaceuticals

    See if you can join NCT06905197 on ClinicalTrials.gov

19. Promoting Immunotherapy Efficacy With Low-Dose Liver RT

    The purpose of this study is to see if adding Low-Dose Liver Radiation (LD-LRT) improves progression free survival (PFS). This study is for patients with either melanoma or non-small cell lung cancer (NSCLC), with liver metastases, and receiving immunotherapy.

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Cincinnati Medical Center, Cincinnati, Ohio

    Run by

    Jordan Kharofa

    See if you can join NCT07225036 on ClinicalTrials.gov

20. A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

    The goal of this Open-Label Study is to evaluate the safety and tolerability of PRTH-101 alone or in combination with pembrolizumab in adults with advance or metastatic solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Honor Health Research Institute, Scottsdale, Arizona

    Locations

    11 in total

    Run by

    Incendia Therapeutics

    See if you can join NCT05753722 on ClinicalTrials.gov

21. A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer

    The purpose of this study is to find out how many people with HER2-amplified or HER2-mutated non-small cell lung cancer (NSCLC) experience a decrease in tumor viability when they receive trastuzumab deruxtecan before routine surgery to remove tumors.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

    Locations

    10 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07428044 on ClinicalTrials.gov

22. Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy

    A comparison of baseline tumor characteristics in oncogene-driven cancers to tumor characteristics after early response to Tyrosine Kinase Inhibitor (TKI) targeted treatment will allow identification of early adaptive mechanisms of cell survival. This will facilitate targeting and termination of th…

    Stage

    Not phased

    Ages

    18 to 85

    Site

    University of Colorado, Cancer Center, Aurora, Colorado

    Run by

    University of Colorado, Denver

    See if you can join NCT03042221 on ClinicalTrials.gov

23. Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

    The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: * Does CP-383 slow or stop the growth of cancer in patients with advanced cancer * What medical prob…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sarah Cannon Research Institute at HealthONE, Denver, Colorado

    Locations

    13 in total

    Run by

    Tasca Therapeutics

    See if you can join NCT07030257 on ClinicalTrials.gov

24. GEMINI-NSCLC: NSCLC Biomarker Study

    GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecul…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Alabama Oncology, Birmingham, Alabama

    Locations

    58 in total

    Run by

    Tempus AI

    See if you can join NCT05236114 on ClinicalTrials.gov

25. Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer

    This is a phase 1, single-center, open-label study that enrolls adult subjects with extensive stage lung cancer or stage IV non-small cell lung cancer that is platinum-refractory and received PD-1 and/or PD-L1 therapy. The purpose of this study is to test the safety of using a new treatment called …

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT05620342 on ClinicalTrials.gov